Restrictions on Publication. Upon the signing of this Agreement and upon exercise of any of the Option Fields of Use under 5.2, both parties shall be entitled to make public — through a press release or otherwise - that Licensee has taken a license to the Patents from the Licensor. Such press-release or similar shall be in a form reasonably acceptable to the other party and shall not disclose any of the financial terms agreed in this Agreement. Within thirty (30) days of the effective date of this Agreement, Licensee will publish on its corporate website that it has taken a license from Licensor under the Patents. Under all other circumstances, neither party shall use the other’s name nor any variation thereof, nor any emblem, logo, trademark or variation thereof, nor the name of any employee in any press releases, advertising, promotional or sales literature, or in any securities reports required by the Securities and Exchange Commission, without the prior written consent of the other party in each case; provided however, that both parties (a) may refer to publications by employees of the other party in the scientific literature, (b) may only state that a non-exclusive, royalty-bearing patent license from Licensor to Licensee has been granted (excluding financial terms) and (c) may make such disclosures as required by law.
Restrictions on Publication. Neither Party nor its Affiliates shall publish or publicly disclose the results generated during the course of performing the Research Plans, or in the Development or Commercialization activities directed to any Selected Target conducted by either Party under this Agreement without the prior written consent of the other Party, except as otherwise expressly permitted in this Section 9.6, in Section 9.7 or otherwise in this Agreement, including in Section 9.3.2. Both Parties (and their respective Affiliates and Sublicensees) shall be permitted to publish or publicly disclose results of activities conducted under the Research Plans under the Collaboration, subject to the prior review by the other Party for patentability and protection of its Confidential Information as described in this Section 9.6. In addition, GSK (and its Affiliates and Sublicensees) shall be permitted to publish or publicly disclose results generated in the course of conducting the Research Plans, or in the Development and Commercialization activities hereunder relating to Licensed Compounds and Licensed Products that are directed to Selected Targets, subject to the prior review by EPIZYME for patentability and protection of its Confidential Information as described in this Section 9.6. Notwithstanding the foregoing, as between EPIZYME and GSK, only EPIZYME shall have the right to publish or publicly disclose results of Collaboration activities (but not Confidential Information of GSK generated outside of the Collaboration) related to any Dropped Target, EPIZYME Compound or EPIZYME Product, and EPIZYME shall have the right to do so (a) in the case of Dropped Targets, EPIZYME Compounds or EPIZYME Products as to which EPIZYME is in possession of Confidential Information of GSK that GSK generated outside the Collaboration, subject to the submission and review procedure set forth in this Section 9.6 and (b) otherwise, without being subject to the submission and review procedure set forth in this Section 9.6.
Restrictions on Publication. Neither Party nor its Affiliates nor its Sublicensees shall publish or publicly disclose the results generated during the course of performing the Research Plan or Development Plans, or otherwise in the Development or Commercialization activities directed to any Available Target, Selected Target, Lapsed Target or Terminated Target conducted by either Party under this Agreement without the prior written consent of the other Party, except as otherwise expressly permitted in this Article 9, including the remainder of this Section 9.6 and Section 9.7, but in all cases subject to the prior review by the other Party for patentability and protection of its Confidential Information as described in this Section 9.6.
Restrictions on Publication. Neither Party nor its Affiliates shall publish or publicly disclose the results generated in the course of performing any of the Development or Commercialization activities directed to EZH2 conducted by either Party under this Agreement without the prior written consent of the other Party, except as otherwise expressly permitted in this Section 10.7, in Section 10.8 or otherwise in this Agreement. The Parties recognize that it may be useful or required to publish or publicly disclose the results of Development activities conducted hereunder, and each Party (and its Affiliates and Sublicensees) shall be free to publish or publicly disclose such results, subject to the prior review by the other Party for patentability and protection of its Confidential Information as described in this Section 10.7.
Restrictions on Publication. Felicitex is entitled to publish or publicly disclose the results generated in the course of this Agreement without the prior written consent of Selvita, but only after submission to and review by Selvita pursuant to Section 10.7.2. Selvita is entitled to publish or publicly disclose the results generated in the course of this Agreement after submission to and review by Felicitex pursuant to Section 10.7.2. and subject to the prior written consent of Felicitex. Felicitex acknowledges that Selvita has certain obligations to publish or publicly disclose the results generated in the course of performing the Research Collaborationunder the SEL141 Grant and the related grant agreement with the Polish Agency for Enterprise Development. Felicitex will consider these obligations in a supportive manner. Exhibit D
Restrictions on Publication. Each Party recognizes that the publication of papers regarding results of and other information regarding activities under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided such publications are subject to reasonable controls to protect each Party’s Confidential Information. Without limiting the disclosures permitted by Section 12.3, it is the intent of the Parties to maintain the confidentiality of any Confidential Information of the non-publishing Party included in any patent application until such patent application has been filed. Accordingly, each Party shall have the right to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains Clinical Data, or pertains to results of Clinical Trials or other studies, with respect to Rifaximin Products or includes other data generated under this Agreement or which includes Confidential Information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a complete copy of the paper or materials for oral presentation to the other Party. The other Party shall review any such paper and give its comments to the publishing Party within [*] days of the delivery of such paper to the other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as soon as practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than [*] days from the date of delivery to the other Party. If the other Party does not respond by the end of such [*] day period, its consent to publication of such papers or presentation of such materials shall be deemed to have been given. Notwithstanding anything to the contrary set forth herein, neither Party may publish any data or information of the other Party that is the other Party’s Confidential Information without the prior written consent of the other Party, such consent not to be unreasonably withheld or delayed, except as permitted by Section 12.3. A Party’s consent to publication or presentation may be conditioned on the publishing or presenting Party (a) complying with the other Party’s request to delete references to such other Party’s Confidential Information in any such paper and (b) withho...
Restrictions on Publication. In no event may any publication or other disclosure contain a Party's Confidential Information without such Party's prior written consent. Ligand shall not publish the results of the Research Program or the results of the Pre-Clinical Development or the Clinical Development of any Collaboration Lead Compound or any other information or data relating to a Collaboration Compound, Collaboration Lead Compound or Product without BMS' prior written consent. BMS may publish the results of the Pre-Clinical Development and Clinical Development without Ligand's prior written consent provided that no such publication shall contain Confidential Information solely owned by Ligand.
Restrictions on Publication. Neither Party nor its Affiliates nor its Sublicensees shall publish or publicly disclose the results generated during the course of performing the Research Plan or Development Plans, or otherwise in the Development or Commercialization activities directed to any Available Target, Selected Target, Lapsed Target or Terminated Target conducted by either Party under this Agreement without the prior written consent of the other Party, except as otherwise expressly permitted in this Article 9, including the remainder of this Section 9.5 and Section 9.6, but in all cases subject to the prior review by the other Party for patentability and protection of its Confidential Information as described in this Section 9.5. Notwithstanding the foregoing, this Section 9.5.1 shall not apply to EPIZYME’s publication or public disclosure of results generated in the course of performing the Research Plan or Development Plans, or otherwise in the Development or Commercialization activities directed to [**], during any period when CELGENE or any of its Affiliates is engaging in a [**]; provided however, CELGENE may review and comment on such proposed publications, which comments EPIZYME shall, if timely made, consider in good faith.
Restrictions on Publication. 3.1 If the copyright holder does not grant authorisation for republishing of a monograph or publication, a review article shall be published with references to online sources of the monograph or publication.
Restrictions on Publication. Notwithstanding Paragraph 8.6 above, if --------------------------- the Management Committee lets reason to believe a manuscript reveals a potentially patentable invention, or discloses another Participant's Confidential Background Information or any Confidential Project Information, the Program Manager shall immediately notify the publishing Participant of that fact. In cases where one or more potentially patentable inventions are disclosed, the publishing Participant agrees to delay such publication, submission or public presentation until a U.S. patent application has been filed or for a period not to exceed one hundred eighty tl80] days, whichever occurs first. In the event another Participant's Confidential Background Information or any Confidential Project Information is disclosed, the publishing Participant shall edit such manuscript to delete such Confidential Information prior to any submission or presentation of the manuscript. No manuscript shall be published by any Participant disclosing potentially patentable inventions or such Confidential Information without the prior approval of the Participant or Participants whose potentially patentable invention or Confidential Information is included in such manuscript.
